MT1E and cancer: Compared to the previous report by Coriat et al. presenting a first clinical analysis centred on the measurement of serum levels of AOPP [4], our study brings three important additional pieces of information: i) Firstly, the measurement of MT1 provides a more specific and standardizable analysis for the study of the effects of sorafenib on the redox metabolism of cancer cells than AOPP; ii) Secondly, our study highlights the existence of important individual heterogeneity in terms of the ability of sorafenib to activate the transcription of the MT1 genes.